Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[Ru3O(CH3COO)6(4-pic)2(NO)]PF6 is a triruthenium nitrosyl cluster that acts as a photoactive pro-drug for the delivery of nitric oxide (NO). The complex consists of a triruthenium core coordinated by six acetate ligands, two 4-picoline (4-methylpyridine) ligands, and a nitrosyl group, with a hexafluorophosphate counterion. It is designed to release NO upon irradiation with visible light (e.g., λ = 532 nm) or through redox-mediated reactions in the cellular environment. In preclinical in vitro studies, the compound has demonstrated significant tumoricidal activity against B16F10 melanoma cells, reducing cell viability by up to 90% upon irradiation. The cytotoxicity is primarily attributed to the release of nitric oxide, which acts as the active species to induce cell death.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [Ru3O(CH3COO)6(4-pic)2(NO)]PF6.